title: Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma.
abstract: OBJECTIVE
  We sought to assess the efficacy of combined therapy after superselective arterial cisplatin infusion (SACI) therapy to treat the maxillary squamous cell carcinoma.
  
  
  METHODS
  We conducted a retrospective chart review of 50 patients. After completion of two courses of SACI, 25 of the patients were successively treated by concurrent SACI and radiotherapy (AR), while the other 25 patients were treated by surgery with postoperative radiotherapy (ASR).
  
  
  RESULTS
  Patients with surgery (ASR) had an 88% local control rate with 75% disease-free survival rate at 60 months by Kaplan-Meier analysis, compared with 62% disease-free survival rate for patients with AR treatment. A particularly good outcome was obtained in T4 cases of the ASR group (n=8) whose 5-year survival rate was 87% and local control rate was 100%.
  
  
  CONCLUSIONS
  Combined SACI therapy is very effective for the treatment of maxillary squamous cell carcinomas and contributes to the improving prognoses of patients and organ preservation rates.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Tohoku University Hospital, Sendai, Japan. kshiga@orl.med.tohoku.ac.jp
authors.forename: Kiyoto
authors.initials: K
authors.lastname: Shiga
authors.forename: Junkichi
authors.initials: J
authors.lastname: Yokoyama
authors.forename: Sho
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Shigeru
authors.initials: S
authors.lastname: Saijo
authors.forename: Masaru
authors.initials: M
authors.lastname: Tateda
authors.forename: Takenori
authors.initials: T
authors.lastname: Ogawa
authors.forename: Mika
authors.initials: M
authors.lastname: Watanabe
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods*; D008297:Male; D008437:Maxilla / Q000473:pathology / Q000601:surgery; D008444:Maxillary Sinus Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D008875:Middle Aged; D009367:Neoplasm Staging; D017233:Orbit Evisceration
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin